Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

66.17
-1.3400-1.98%
Post-market: 66.170.00000.00%19:30 EDT
Volume:1.15M
Turnover:76.94M
Market Cap:6.24B
PE:-138.88
High:68.73
Open:67.76
Low:66.11
Close:67.51
52wk High:68.73
52wk Low:22.06
Shares:94.26M
Float Shares:92.77M
Volume Ratio:0.91
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:254.35
PE(LYR):-231.08

Loading ...

Stock Track | Travere Therapeutics Soars 5.99% Intraday on Multiple Analyst Price Target Raises

Stock Track
·
May 05

Travere Therapeutics Inc : Jefferies Raises Target Price to $54 From $50

THOMSON REUTERS
·
May 05

Piper Sandler Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
May 05

Travere Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $57 From $47

THOMSON REUTERS
·
May 05

Travere Therapeutics Inc : Leerink Partners Raises Target Price to $55 From $50

THOMSON REUTERS
·
May 05

Travere Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Travere Therapeutics director Roy D. Baynes disposes of USD 431,145 common shares

Reuters
·
May 05

Travere Therapeutics Q1 product sales rise on FILSPARI demand

Reuters
·
May 05

Travere Q1 FY26 net loss narrows to $37.1 million; net product sales climb 64.1% to $124.5 million

Reuters
·
May 05

BRIEF-Travere Therapeutics Q1 EPS USD -0.4

Reuters
·
May 05

Travere Therapeutics Q1 Operating Income USD -36.915 Million

THOMSON REUTERS
·
May 05

Press Release: Travere Therapeutics Reports First Quarter 2026 Financial Results

Dow Jones
·
May 05

Travere Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
May 02

Travere Therapeutics (TVTX) Gets a Buy from Guggenheim

TIPRANKS
·
Apr 29

Press Release: Travere Therapeutics to Report First Quarter 2026 Financial Results

Dow Jones
·
Apr 28

Travere Therapeutics to report quarterly results, host conference call

Reuters
·
Apr 28

A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI’s Expanded FDA Approval In FSGS

Simply Wall St.
·
Apr 25

Travere Therapeutics Inc : Jefferies Raises Target Price to $50 From $42

THOMSON REUTERS
·
Apr 24

Travere Therapeutics (TVTX) Receives a Buy from Piper Sandler

TIPRANKS
·
Apr 24

A Look At Travere Therapeutics (TVTX) Valuation After FDA Expands FILSPARI Approval For FSGS

Simply Wall St.
·
Apr 18